XAIR · XBRL financial data

Beyond Air financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (XAIR's year ends in late March)

In millions of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025†Mar 31, 2025	FY 2026Mar 31, 2026
Revenue from contracts with customers	1	—	—	1	4	8
Cost of revenue	—	—	1	2	5	7
Gross profit	—	—	(1)	(1)	(2)	0
Research and development	13	12	17	24	17	10
Selling, general and administrative	—	—	—	37	26	19
General and administrative	10	18	35	37	—	—
Total operating expenses	—	41	52	62	43	29
Operating income (loss)	(22)	(41)	(52)	(63)	(45)	(29)
Interest expense	1	1	0	3	3	4
Other income (expense)	—	—	—	(0)	0	(0)
Net income (loss)	(23)	(43)	(56)	(60)	(47)	(33)
Earnings per share, basic USD per share	(1.27)	(1.68)	(1.86)	(1.82)	(0.69)	(4.01)
Earnings per share, diluted USD per share	—	—	(1.86)	(1.82)	(0.69)	(4.01)
Weighted average shares, basic millions of shares	18,005	25,668	30	33	68	8
Weighted average shares, diluted millions of shares	—	—	30	33	68	8

† Share count changed about 2x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (XAIR's year ends in late March)

In millions of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025†Mar 31, 2025	FY 2026Mar 31, 2026
Cash and cash equivalents	35	80	29	11	5	7
Marketable securities	—	—	17	23	2	5
Marketable securities, non-current	—	—	0	0	—	—
Accounts receivable	—	—	—	0	1	1
Inventory	—	0	1	2	2	1
Prepaid and other current assets	2	2	2	7	6	5
Total current assets	37	93	59	44	16	25
Property and equipment, net	1	2	5	9	11	8
Right-of-use asset	2	2	2	2	2	1
Total assets	41	99	69	57	30	35
Accounts payable	1	1	2	2	2	2
Accrued liabilities	2	8	17	—	—	—
Total current liabilities	4	11	20	12	5	7
Lease liability, non-current	2	2	2	2	1	1
Total liabilities	10	21	27	30	16	29
Accumulated deficit	(80)	(124)	(179)	(240)	(286)	(320)
Total stockholders' equity	30	73	38	25	14	6
Total liabilities and equity	41	99	69	57	30	35
Common shares outstanding (cover page) millions of shares	22	30	32	46	93	14

† Share count changed about 2x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (XAIR's year ends in late March)

In millions of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025†Mar 31, 2025	FY 2026Mar 31, 2026
Net income (loss)	(23)	(43)	(56)	(60)	(47)	(33)
Stock-based compensation	5	8	20	21	9	5
Depreciation and amortization	0	0	—	—	—	—
Net cash from operating activities	(20)	(23)	(33)	(56)	(38)	(18)
Purchases of property and equipment	1	1	4	6	6	1
Net cash from investing activities	(1)	(1)	(21)	(12)	15	(4)
Proceeds from issuing common stock	—	25	—	—	19	5
Proceeds from issuing equity	50	—	—	—	—	—
Net cash from financing activities	30	79	3	43	17	29
Net change in cash	10	55	(51)	(25)	(7)	7

† Share count changed about 2x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Beyond Air	5.5	1.8	(4.9)	957,631	2.0 quarters	Q1 FY27 10-QJun 30, 2026
RetinalGenix Technologies	0	not reported	(0.1)*	18.8M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Harvard Apparatus Regenerative Technology	0.4	0.4	(0.6)*	17.6M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Nexalin Technology	1	0	(1.8)*	22.0M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Iridex	4.7	13	0.2*	17.6M	—	Q2 FY26 10-QJul 4, 2026
Biotricity	0.5	4.3	0.5	19.9M	—	Q1 FY27 10-QJun 30, 2026
Encision	0.1	1.5	(0.1)*	16.9M	0.6 quarters	Q2 FY26 10-QSep 30, 2025
VASO	38	not reported	17*	176.0M	—	Q2 FY26 10-QJun 30, 2026
Envoy Medical	20	0.1	(5.5)*	77.2M	3.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.